Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 416-423

  Xu, Zhen Hua ^a   Wang, Wei ^a   Zhao, Xue Jun ^a   Huang, Song Lin ^a   Zhu, Bing ^a   He, Nan ^a   Shu, Yan ^a   Liu, Zhao Qian ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP2C19; CYP2C9; Cytochrome P450; Demethylsertraline; Drug metabolism; Human liver microsomes; Monoclonal antibody; Omeprazole; Pharmacogenetics; Selective serotonin reuptake inhibitor; Sertraline; Sulphaphenazole

Indexed keywords

COUMARIN; CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; ENZYME INHIBITOR; FURAFYLLINE; KETOCONAZOLE; MONOCLONAL ANTIBODY; OMEPRAZOLE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFAPHENAZOLE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; METHYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0032840038     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00023.x     Document Type: Article

References (26)

1. Heym J, Koe BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988; 49(Suppl): 40-45.
2. Murdoch D, McTavish D. Sertraline, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992; 44: 604-624.
3. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HF., Loft S. Fluvoxamine is a potent inhibitor of cytochrome CYP1A2. Biochem Pharmacol 1993; 45: 1211-1214.
4. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151-159.
5. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effects of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-265.
6. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of Selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481-485.
7. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996; 42: 518-521.
8. Schmider J, Greenblatt D, von Moltke LL, Karsov D, Shader RI. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44: 495-498.
9. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
10. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and demethylsertraline on human CYP3A catalyzed 1′ hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995; 275: 1131-1135.
11. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokin 1997; 32(Suppl 1): 1-21.
12. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drag interactions and cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokin 1995; 29(Suppl): 10-18.
13. Solai LK, Mulsant BH, Pollock BG, et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997; 58: 440-443.
14. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in PMs of debrisoquin. Clin Pharmacol Ther 1996; 60: 512-521.
15. de Morais SMF, Goldstein JA, Xie HC, et al. Genetic analysis of the S mephenytion polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411.
16. von Bahr C, Groth CG, Jansson H, Lundgren G, Lind M, Glaumann H. Drug metabolism in human liver in vitro: Establishment of a human liver bank. Clin Pharmacol Ther 1980; 27: 711-725.
17. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement with Folin phenol reagents. J Biol Chem 1951; 193: 265-275.
18. Tremaine LM, Joerg EA. Automated gas chromatographic-electron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496: 423-429.
19. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI. Enzyme kinetic modelling as a tool to analyse the behavior of cytochrome P450 catalyzed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 1996; 41: 593-604.
20. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
21. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrate in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45: 107-114.
22. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-137.
23. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862.
24. Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from in vitro experiments. J Pharmacol Exp Ther 1997; 280: 730-738.
25. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: Cosegrregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 1993; 266: 52-59.
26. Minors JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45 (525-538): 27.